Related Experiment Video

Updated: Jun 3, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with

P Schöffski1, M Taron, J Jimeno

  • 1Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Catholic University Leuven, B-3000 Leuven, Belgium. patrick.schoffski@uzleuven.be

European Journal of Cancer (Oxford, England : 1990)
|March 8, 2011
PubMed
Abstract

Insights

Tumor DNA repair profiles, specifically low BRCA1 and high XPG or ERCC1 mRNA expression, predict better outcomes for advanced sarcoma patients treated with trabectedin. This DNA repair signature identifies sensitive patient populations for improved treatment response.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Trabectedin efficacy is influenced by DNA repair pathways.
  • Nucleotide excision repair (NER) enhances sensitivity, while homologous recombination repair (HRR) confers resistance.

Purpose of the Study:

  • To investigate the correlation between DNA repair gene mRNA expression and trabectedin treatment outcomes in sarcoma patients.
  • To identify predictive biomarkers for trabectedin response in advanced sarcomas.

Main Methods:

  • Retrospective analysis of mRNA expression of BRCA1, XPG, and ERCC1 in tumor samples from 245 advanced sarcoma patients.
  • Quantitative real-time polymerase chain reaction (qRT-PCR) for gene expression analysis.
  • Median values used as cut-offs for low/high mRNA expression.

Main Results:

  • Low BRCA1 mRNA expression correlated with significantly better response to trabectedin.
  • High XPG expression was significantly associated with increased drug response.
  • A composite signature (low BRCA1 and high ERCC1/XPG) identified a highly sensitive sarcoma population with improved outcomes.

Conclusions:

  • DNA repair profiles serve as predictive biomarkers for trabectedin treatment outcomes in advanced sarcoma.
  • The identified signature warrants evaluation in prospective studies to enrich for sensitive patient populations in sarcoma and other malignancies.

More Related Videos

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...